URI:
   DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: COPAXONE, GLATOPA (glatiramer acetate)
       *****************************************************
       #Post#: 4708--------------------------------------------------
       Real-world pharmacovigilance study of drug-induced autoimmune he
       patitis from FAERS database
       By: agate Date: February 9, 2025, 3:21 pm
       ---------------------------------------------------------
       From Nature (February 8, 2025)--"Real-world pharmacovigilance
       study of drug-induced autoimmune hepatitis from the FAERS
       database":
  HTML https://www.nature.com/articles/s41598-025-89272-x
       This part concerns glatiramer acetate:
       [quote][font=-apple-system]Glatiramer acetate, commonly used for
       multiple sclerosis due to its favorable safety profile, has been
       implicated in over 50 reported cases of liver injury in the
       FAERS [FDA Adverse Event Reporting System] database. Among
       these, 3 cases involved classic AIH requiring prolonged
       immunosuppressive therapy[/font][font=-apple-system], and 5
       cases presented with transient elevations in antinuclear
       antibodies or smooth muscle antibodies, indicative of
       immune-mediated liver injury[/font][font=-apple-system]. The
       exact mechanism remains unclear, but potential pathways include
       Th2 cell induction or mitochondrial
       damage[/font][font=-apple-system].[/font] [font=-apple-system]
       Routine liver function monitoring is recommended during the
       initial 6 months of treatment, particularly for elderly
       patients, those with chronic liver disease, or those with a
       history of DILI [drug-induced liver injury].[/font][/quote]
       *****************************************************